Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on days 1 and 15 in 4-wk cycles), combined with low-dose cytarabine (LDAC; 20 mg subcutaneous, twic...
Main Authors: | Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel A. Sanz, Achilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee-Je Kim, Je-Hwan Lee, Kensuke Usuki, Stefano D'Ardia, Chul Won Jung, Olga Salamero, Heinz-August Horst, Christian Recher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valerie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2021-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000617 |
Similar Items
-
Inhibition of Suicidal Erythrocyte Death by Volasertib
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2017-10-01) -
Volasertib for AML: clinical use and patient consideration
by: Hao Z, et al.
Published: (2015-07-01) -
Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression
by: Mi-Yeon Jeon, et al.
Published: (2017-11-01) -
New drugs for low grade lymphoproliferative diseases
by: Argiris Symeonidis
Published: (2020-10-01) -
Anaerobic fermentation of lysine
by: Dohner, Patricia Marie, 1929-
Published: (1952)